Solid Biosciences Q2 FY26 net loss widens 38.8% to $54.8 million
SLDB•Q2 FY26 financial results
- Solid Biosciences posted a GAAP net loss of $54.8 million, widening 38.8% year over year.
- GAAP operating loss widened to $57.4 million, driven by operating expenses of $57.4 million, up 37.6% year over year.
- GAAP R&D expense climbed to $44.3 million, up 36.6%, on higher SGT-003 manufacturing and clinical costs.
- GAAP G&A expense rose to $13.1 million, up 41.4%, mainly on higher personnel-related costs.
- Cash, cash equivalents and available-for-sale securities totaled $377.7 million at June 30, 2026; runway expected into mid-2028.
